National surveillance of antimicrobial susceptibilities of Neisseria gonorrhoeae annual summary 2019

Executive summary

Figure A. Trends of MDR-GC Neisseria gonorrhoeae in Canada from 2015 to 2019Footnote a
Figure A. Trends of MDR-GC <em>Neisseria gonorrhoeae</em> in Canada from 2015 to 2019
Footnote a

Percentage based on total number of isolates tested nationally: 2015=4190; 2016=4538; 2017=5290; 2018=5607; 2019=4859

Return to footnote a referrer

Figure A - Text Description

A combination bar and line graph displaying the trending of MDR-GC in Canada from 2015 to 2019 by percentage based on total number of isolates tested nationally (line graph) and by number (bar graph).

Figure A. Trends of MDR-GC Neisseria gonorrhoeae in Canada from 2015 to 2019Table 1 Footnote a
Year (number of cultures tested nationally) MDR (%) MDR (n)
2015 (N=4190) 8.6% 361
2016 (N=4538) 8.9% 406
2017 (N=5290) 12.2% 645
2018 (N=5607) 8.0% 446
2019 (N=4859) 12.4% 601
Figure B. Trends of XDR-GC Neisseria gonorrhoeae in Canada from 2015 to 2019Footnote a
Figure B. Trends of XDR-GC <em>Neisseria gonorrhoeae</em> in Canada from 2015 to 2019
Footnote a

Percentage based on total number of isolates tested nationally: 2015=4190; 2016=4538; 2017=5290; 2018=5607; 2019=4859

Return to footnote a referrer

Figure B - Text Description

A combination bar and line graph displaying the trending of XDR-GC in Canada from 2015 to 2019 by percentage based on total number of isolates tested nationally (line graph) and by number (bar graph).

Figure B. Trends of XDR-GC Neisseria gonorrhoeae in Canada from 2015 to 2019Table 2 Footnote a
Year (number of cultures tested nationally) XDR (%) XDR (n)
2015 (N=4190) 0.05% 2
2016 (N=4538) 0.02% 1
2017 (N=5290) 0% 0
2018 (N=5607) 0.12% 7
2019 (N=4859) 0.02% 1
Figure C. Trends of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Tested in Canada, 2015-2019Footnote a
Figure C. Trends of Antimicrobial Susceptibilities of <em>Neisseria gonorrhoeae</em> Tested in Canada, 2015-2019
Footnote a

Percentage based on total number of isolates tested nationally: 2015=4190; 2016=4538; 2017=5290; 2018=5607; 2019=4859

Return to footnote a referrer

Figure C - Text Description

A line graph with three lines representing Neisseria gonorrhoeae isolates resistant to azithromycin, decreased susceptibility to cefixime and decreased susceptibility to ceftriaxone in Canada from 2015 to 2019.

Figure C. Trends of Antimicrobial Susceptibilities of Neisseria gonorrhoeae Tested in Canada, 2015-2019Table 3 Footnote a
Antibiotic 2015 2016 2017 2018 2019
Ceftriaxone - (DS) Decreased Susceptibility 144 (3.4%) 80 (1.8%) 30 (0.6%) 31 (0.6%) 40 (0.8%)
Cefixime - (DS) Decreased Susceptibility 79 (1.9%) 14 (0.3%) 32 (0.6%) 27 (0.5%) 71 (1.5%)
Azithromycin - (R) Resistant 198 (4.7%) 327 (7.2%) 613 (11.6%) 427 (7.6%) 597 (11.7%)
Figure D. Trends of Emerging and Prevalent NG-MAST Sequence Types of Neisseria gonorrhoeae Isolates Tested by NML, 2015 – 2019Footnote b
Figure D. Trends of Emerging and Prevalent NG-MAST Sequence Types of <em>Neisseria gonorrhoeae</em> Isolates Tested by NML, 2015 – 2019
Footnote b

A total of 396 sequence types in 2015, 490 sequence types in 2016, 468 sequence types in 2017, 503 sequence types in 2018 and 464 sequence types in 2019. Only the most prevalent sequence types of 2015 to 2019 are represented in this graph.

Return to footnote b referrer

Figure D - Text Description

A stacked bar graph displaying trending of three of the most prevalent NG-MAST sequence types in Canada from 2015 to 2019 and antimicrobial resistance associated with them.

Figure D. Trends of Emerging and Prevalent NG-MAST Sequence Types of Neisseria gonorrhoeae Isolates Tested by NML, 2015 – 2019Table 4 Footnote b
NG-MAST Year CipR with or without other resistances TRNG with or without other resistances AziR/EryR and AziR/CipR/EryR with other resistances
ST-12302 2015 3 0 110
ST-12302 2016 84 0 240
ST-12302 2017 312 0 375
ST-12302 2018 390 0 225
ST-12302 2019 66 0 278
ST-14994 2015 0 0 0
ST-14994 2016 0 0 0
ST-14994 2017 60 0 0
ST-14994 2017 537 0 23
ST-14994 2019 396 2 15
ST-5985 2015 6 419 0
ST-5985 2016 58 309 0
ST-5985 2017 20 193 0
ST-5985 2018 0 194 0
ST-5985 2019 0 120 0

For more details on the report and its key findings, please email: phac.nml.strepsti-lnm.strepits.aspc@canada.ca.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: